Intellex Acquires Expert by Big Village

We're thrilled to announce that Intellex has acquired Expert by Big Village, effective March 22, 2024. This strategic move enhances our capabilities and strengthens our commitment to delivering exceptional solutions to our customers.

Stay tuned for more updates on how this acquisition will benefit our clients and experts.

For inquiries or more information, please contact us at info@intellex.com.

×

Expert Details

Life Sciences with focus on Cancer Immunology, Assay Development and Bioanalytics

ID: 737766 Germany

Request Expert

Detail-oriented and results-driven professional offering extensive experience in cancer research, assay development and bioanalytics combined with strong understanding of project management. Skilled in planning, designing, and executing various scientific investigations in support of assay development. Adept at delivering technical leadership to projects from inception through commercialisation and launch. Demonstrated capacity to create efficient operational models, covering assay instrumentation, design and analysis.

Education

Year Degree Subject Institution
Year: 2008 Degree: Diploma Subject: Biology Institution: Technical University Kaiserslautern, Germany

Work History

Years Employer Title Department
Years: 2020 to Present Employer: Undisclosed Title: Head of Assay Development and Bioanalytics Department: Assay Development and Bioanalytics
Responsibilities:
Steer all day-to-day operations of the Assay Development department. Provide services to technical personnel as Line Manager. Formulate and deliver comprehensive reports to management ensuring informed decision making. Deliver effective technical support to develop new assays and to implement current methodologies. Support onboarding of two new team members. Formulate comprehensive study reports and presentations.
● Create CoAs while administering analytics pertaining to CGE, HPLC, biological activity and HCP for in-house generated proteins.
● Plan, write and review pre-clinical study plans and reports as well as support analytics for clinical studies.
Years Employer Title Department
Years: 2018 to 2020 Employer: Apogenix AG Title: Laboratory Manager Assay Development and Bioanalytics Department: Assay Development and Bioanalytics
Responsibilities:
Formulated and optimized biochemical/cellular assays such as PK-analytics, ADA, nAbs, and cytokines. Transferred internally designed assays to CROs which subsequently performed the assays under GLP-conditions; analysed data sent back by the CROs. Represented Apogenix on several international conferences, including AACR, World Immune Regulation Meeting and Festival of Biological to increase visibility of products to scientific or commercial partners.
● Created CoAs while administering analytics pertaining to CGE, HPLC, biological activity, and HCP for in-house generated proteins.
● Developed three different products from the pre-clinical status to a ready-to-go IND.
● Analysed pre-clinical study plans and reports as well as supported analytics for clinical studies.
Years Employer Title Department
Years: 2014 to 2018 Employer: BioMed X Innovation Center Title: Senior Scientist (Postdoc) Department: Research group "Immunosuppressive Microenvironment of Tumors"
Responsibilities:
Conducted phenotypic and functional analysis of immune cells (MDSC, DC) with FACS, ELISA and microscopy. Oversaw the preparation of cells/tissue, isolated RNA/DNA, performed RNA-sequencing and interpreted the generated results thereof. Executed all end-to-end operations of internal and external results ranging from analysis, interpretation to presentation. Performed high-throughput screening assays with primary myeloid cells and tumour cell lines.
● Led and optimised personal competencies of one technician and two research associates.
● Achieved desired results through effective planning and supervision of experiments.
● Established lab from scratch by ordering new machines and lab material as well as setting up all new techniques
Years Employer Title Department
Years: 2011 to 2014 Employer: University Clinic of Bonn Title: Senior Scientist (Postdoc) Department: Experimental Immunology
Responsibilities:
Collaborated with Evonik and Merck KGaA to formulate nanoparticulate carrier for varied applications. Managed a team comprised of one technician and one research associate to accomplish targeted research. Planned, executed, and supervised experiments while performing pharmacodynamic / -kinetic analyses in mice. Delivered exceptional results, resulting in securing a patent with Merck and winning the Nanomedicine Award 2015.
● Utilised FACS and microscopy for in-depth analysis of the nanoparticle uptake mechanism.
● Optimised coating of nanoparticles to increase their intake in different cell types including macrophages, T cells, B cells and tumor cell lines by nanoparticle formulations screening
Years Employer Title Department
Years: 2008 to 2011 Employer: University Clinic of Frankfurt am Main Title: PhD Student Department: Immunepharmacology
Responsibilities:
During my Ph.D. phase I investigated the impact of sphingosine kinases on activation and development of dendritic cells. I worked with transgenic mice, used basic and advanced immunological techniques and established a detection method with LC-ESI-MS/MS in a cooperation.

Career Accomplishments

Licenses / Certifications
Preclinic compact. FORUM Institute for management GmbH. June 2021

FELASA B Zertifikat (animal experiment qualification) Since September 2009.

IATA certificate March 2021

ECA certified Biotech Manager. ECA Academy. Sept. 2019
Professional Appointments
PhD student at the Universitiy Clinic of Frankfurt am Main
Senior Scientist at the University Clinic of Bonn
Senior Scientist at BioMed X Innovation Center, Heidelberg
Laboratory Manager Assay Development and Bioanalytics at Employer, Heidelberg
Head of Assay Development and Bioanalytics at Employer, Heidelberg
Awards / Recognition
Nanomedicine Award 2015 for the Best Nanomedicine Early Clinical Stage Project - "Inhalable chitosan-based nano-in-microparticles for mucosal therapeutic vaccination
Publications and Patents Summary
1 Patent:
Antigen-loaded chitosan nanoparticles for immunotherapyAntigen-loaded chitosan nanoparticles for immunotherapy DE WO/2015/185180

The present invention is directed to nanoparticles comprising chitosan and an antigen, whereby the chitosan has a degree of deacetylation of about 90% and a molecular weight from 5 kDa to 80 kDa, to microparticles containing such nanoparticles as well as to a process for preparation of such particles. The particles are usable for vaccination.

13 Publications in total:
The sphingosine kinase 1 and S1P1 axis specifically counteracts LPS-induced IL-12p70 production in immune cells of the spleenThe sphingosine kinase 1 and S1P1 axis specifically counteracts LPS-induced IL-12p70 production in immune cells of the spleen
Molecular Immunology · 1. Mai 2011


LC-MS/MS determination of FTY720 and FTY720-phosphate in murine intracellular compartments and human plasma.LC-MS/MS determination of FTY720 and FTY720-phosphate in murine intracellular compartments and human plasma.
J Chromatogr B Analyt Technol Biomed Life Sci · 30. Jan. 2012

CXCL9 causes heterologous desensitization of CXCL12-mediated memory T lymphocyte activationCXCL9 causes heterologous desensitization of CXCL12-mediated memory T lymphocyte activation
Journal of Immunology · 1. Apr. 2013

The role of the Tra1p transcription factor of Magnaporthe oryzae in spore adhesion and pathogenic developmentThe role of the Tra1p transcription factor of Magnaporthe oryzae in spore adhesion and pathogenic development
Fungal Genet Biol · 31. Mai 2013


Modulation of IL-33/ST2-TIR and TLR signalling pathway by fingolimod and analogues in immune cells.Modulation of IL-33/ST2-TIR and TLR signalling pathway by fingolimod and analogues in immune cells.
Scand J Immunol · 1. Dez. 2014

Subcellular distribution of FTY720 and FTY720-phosphate in immune cells - another aspect of Fingolimod action relevant for therapeutic application.Subcellular distribution of FTY720 and FTY720-phosphate in immune cells - another aspect of Fingolimod action relevant for therapeutic application.
Biol. Chem. · 1. Juni 2015

Antigen delivery via hydrophilic PEG-b-PAGE-b-PLGA nanoparticles boosts vaccination induced T cell immunityAntigen delivery via hydrophilic PEG-b-PAGE-b-PLGA nanoparticles boosts vaccination induced T cell immunity
European Journal of Pharmaceutics and Biopharmaceutics · 1. März 2016

Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening / Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening
Oncoimmunology · 1. Jan. 2017

The activity of myeloid cell-specific VHH immunotoxins is target-, epitope-, subset- and organ dependent.The activity of myeloid cell-specific VHH immunotoxins is target-, epitope-, subset- and organ dependent.
Scientific Reports · 20. Dez. 2017


Sortaggable liposomes: Evaluation of reaction conditions for single-domain antibody conjugation by Sortase-A and targeting of CD11b+ myeloid cellsSortaggable liposomes: Evaluation of reaction conditions for single-domain antibody conjugation by Sortase-A and targeting of CD11b+ myeloid cells
European Journal of Pharmaceutics and Biopharmaceutics · 1. Sept. 2018


Genetic screen in myeloid cells identifies TNF-α autocrine secretion as a factor increasing MDSC suppressive activity via Nos2 up-regulation.Genetic screen in myeloid cells identifies TNF-α autocrine secretion as a factor increasing MDSC suppressive activity via Nos2 up-regulation.
Scientific Reports · 7. Sept. 2018


Sortagging of liposomes with a murine CD11b-specific VHH increases in vitro and in vivo targeting specificity of myeloid cells.Sortagging of liposomes with a murine CD11b-specific VHH increases in vitro and in vivo targeting specificity of myeloid cells.
Eur J Pharm Biopharm. · 20. Nov. 2018

HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionalityHERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality
Jurnal for Immunotherapy of Cancer · 1. Aug. 2019

Additional Experience

Expert Witness Experience
https://www.everydays.de/pages/dr-Expert-schroeder
https://crispr-bte.com/course-and-certification-program/

Language Skills

Language Proficiency
German Native
English Fluent

Fields of Expertise

Request Expert

Dev Tool:

Request: expert/life-sciences-with-focus-on-cancer-immunology-assay-development-and-bioanalytics
Matched Rewrite Rule: expert/([^/]+)(?:/([0-9]+))?/?$
Matched Rewrite Query: experts=life-sciences-with-focus-on-cancer-immunology-assay-development-and-bioanalytics&page=
Loaded Template: single-experts.php